Journal article icon

Journal article

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

Abstract:

Background

The replication-competent recombinant vesicular stomatitis virus (rVSV)–based vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety and immunogenicity testing before its use in West Africa.

Methods

We performed three open-label, dose-escalation phase 1 trials and one randomized, double-blind, controlled phase 1 trial to assess the safety, side-effect profile, and immunogenicity of rVSV-ZEBOV at various doses in 158 hea...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1056/NEJMoa1502924

Authors


Expand authors...
German National Department for Education and Research More from this funder
German Center for Infection Research More from this funder
Wellcome Trust More from this funder
U.S. Army Medical Research Institute of Infectious Diseases More from this funder
Austrian Federal Ministry of Science, Research, and Economy More from this funder
Expand funders...
Publisher:
Massachusetts Publisher's website
Journal:
New England Journal of Medicine Journal website
Volume:
374
Issue:
17
Pages:
1647-1660
Publication date:
2016-04-01
DOI:
EISSN:
1533-4406
ISSN:
0028-4793
Source identifiers:
522529
Pubs id:
pubs:522529
UUID:
uuid:660ee87b-dc3d-4343-866a-58db3b677b67
Local pid:
pubs:522529
Deposit date:
2017-10-19

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP